Kwick Forensic Solutions

Founded in March 2005, Kwick Forensic Solutions has evolved into a premier provider of forensic technology in India. Over nearly two decades, the company has built a comprehensive portfolio that addresses the critical needs of crime scene investigation and digital evidence recovery.

The company's core business model revolves around the development and supply of high-tech forensic products. Its offerings include fingerprint and physical evidence kits, DNA forensic solutions, and sophisticated Mobile Crime Scene Investigation Vehicles. Additionally, they provide digital forensic tools and social-media analytics to modernize criminal investigations.

Kwick Forensic Solutions serves a prestigious and stable client base consisting of police departments, central and state forensic laboratories, fingerprint bureaus, and crime investigation departments. Their reach extends to police training academies, universities, and various government and private-sector institutions across India.

Operational strength is driven by a robust R&D focus, ensuring that their laboratory solutions and handheld forensic devices remain at the cutting edge of technology. This R&D capability allows the firm to offer rental services for expensive forensic equipment, lowering the barrier to entry for smaller agencies.

The company is steered by its promoters, Shammer Saralal Shah, Sejal Shammer Shah, and Tulsidas Hinduja Ashok Kumar, who have scaled the business from a niche provider to a significant player in the forensic solutions landscape.

The Kwick Forensic Solutions IPO is a book-build issue seeking to raise approximately ₹50.77 Crores. The structure consists of a significant fresh issue of ₹41.05 Crores and an offer for sale (OFS) of approximately 10.80 Lakh equity shares. The price band is set at ₹85 to ₹90 per share, with a minimum lot size of 3,200 shares requiring an investment of ₹2,88,000. The issue is open from August 27 to August 31, 2026, with listing scheduled for September 3, 2026, on the BSE SME platform.

The proceeds from the fresh issue are primarily earmarked for funding the working capital requirements of the company, amounting to ₹48.00 Crores. This capital infusion is intended to support the company's operational growth and manage its increasing scale of projects.

Financial performance has shown an impressive upward trajectory. Revenue grew from ₹30.26 Crore in FY24 to ₹65.08 Crore in FY25, and further jumped to ₹105.80 Crore in FY26. Net Profit (PAT) followed a similar growth pattern, increasing from ₹2.83 Crore in FY24 to ₹8.56 Crore in FY25, and reaching ₹13.51 Crore in FY26.

From a valuation perspective, the company reports a strong Basic EPS of ₹8.00 for FY26 and an impressive ROE of 38.98%. As there are no direct listed industry peers, the valuation is assessed based on its own growth metrics and the high scarcity value of forensic technology providers in the public market.

Key investment strengths include the high ROCE of 44.88%, a strong growth profile in both top and bottom lines, and a specialized market niche with high barriers to entry. The dominant fresh issue component indicates that the company is raising capital for growth rather than promoters simply exiting.

However, investors should note risks such as the lack of listed peers for relative valuation and the dependence on government contracts. Overall, the IPO presents a growth-oriented opportunity in a specialized sector, though it remains subject to the volatility typical of the SME segment.